NZ599900A - Pharmaceutical suspension aerosol formulations for use in metered dose inhalers - Google Patents

Pharmaceutical suspension aerosol formulations for use in metered dose inhalers

Info

Publication number
NZ599900A
NZ599900A NZ599900A NZ59990010A NZ599900A NZ 599900 A NZ599900 A NZ 599900A NZ 599900 A NZ599900 A NZ 599900A NZ 59990010 A NZ59990010 A NZ 59990010A NZ 599900 A NZ599900 A NZ 599900A
Authority
NZ
New Zealand
Prior art keywords
metered dose
suspension aerosol
particles
aerosol formulations
dose inhalers
Prior art date
Application number
NZ599900A
Other languages
English (en)
Inventor
Lise-Marie Fueg
Rudi Mueller-Walz
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of NZ599900A publication Critical patent/NZ599900A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ599900A 2009-10-16 2010-10-15 Pharmaceutical suspension aerosol formulations for use in metered dose inhalers NZ599900A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918150.4A GB0918150D0 (en) 2009-10-16 2009-10-16 Improved formulations
PCT/EP2010/065569 WO2011045429A1 (en) 2009-10-16 2010-10-15 Improved formulations

Publications (1)

Publication Number Publication Date
NZ599900A true NZ599900A (en) 2014-11-28

Family

ID=41462451

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599900A NZ599900A (en) 2009-10-16 2010-10-15 Pharmaceutical suspension aerosol formulations for use in metered dose inhalers

Country Status (25)

Country Link
US (2) US20120263766A1 (enExample)
EP (2) EP2488157B1 (enExample)
JP (2) JP5818801B2 (enExample)
CN (1) CN102573791B (enExample)
AU (1) AU2010305695B2 (enExample)
BR (1) BR112012008969B1 (enExample)
CA (1) CA2776845C (enExample)
CL (1) CL2012000948A1 (enExample)
CY (1) CY1123918T1 (enExample)
DK (1) DK2488157T3 (enExample)
ES (1) ES2859629T3 (enExample)
GB (1) GB0918150D0 (enExample)
HR (1) HRP20210379T1 (enExample)
HU (1) HUE054030T2 (enExample)
IL (2) IL219162A0 (enExample)
LT (1) LT2488157T (enExample)
MX (1) MX372991B (enExample)
NZ (1) NZ599900A (enExample)
PL (1) PL2488157T3 (enExample)
PT (1) PT2488157T (enExample)
RS (1) RS61430B1 (enExample)
SI (1) SI2488157T1 (enExample)
SM (1) SMT202100150T1 (enExample)
WO (1) WO2011045429A1 (enExample)
ZA (1) ZA201202595B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
WO2013127738A1 (de) * 2012-02-28 2013-09-06 Boehringer Ingelheim International Gmbh Neue treibgashaltige tiotropium-formulierung
RU2678992C2 (ru) 2012-04-11 2019-02-05 Сипла Лимитед Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN105963282B (zh) * 2016-05-04 2019-04-19 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
DE69622166T2 (de) 1995-04-14 2003-04-03 Smithkline Beecham Corp., Philadelphia Dosierinhalator für albuterol
JPH101442A (ja) * 1996-06-12 1998-01-06 Taisho Pharmaceut Co Ltd 鼻炎用点鼻薬
EP1393721B1 (en) * 1997-03-20 2008-11-26 Schering Corporation Dosage form of powder agglomerates
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2001289126A1 (en) 2000-09-18 2002-04-02 Glaxo Group Limited Metered dose inhaler can coated two or more times with fluorocarbon polymers
CN1635870A (zh) * 2000-10-09 2005-07-06 3M创新有限公司 药用气雾剂制剂
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations

Also Published As

Publication number Publication date
PL2488157T3 (pl) 2021-06-28
CA2776845C (en) 2018-04-24
MX372991B (es) 2020-06-18
ES2859629T3 (es) 2021-10-04
CN102573791B (zh) 2017-09-22
RS61430B1 (sr) 2021-03-31
GB0918150D0 (en) 2009-12-02
IL219162A0 (en) 2012-06-28
DK2488157T3 (da) 2021-01-25
HUE054030T2 (hu) 2021-08-30
US20180296468A2 (en) 2018-10-18
JP2016040286A (ja) 2016-03-24
CN102573791A (zh) 2012-07-11
CL2012000948A1 (es) 2012-12-14
BR112012008969B1 (pt) 2021-07-06
MX2012004338A (es) 2012-08-01
PT2488157T (pt) 2021-02-05
ZA201202595B (en) 2023-07-26
JP2013507429A (ja) 2013-03-04
CA2776845A1 (en) 2011-04-21
JP5818801B2 (ja) 2015-11-18
WO2011045429A1 (en) 2011-04-21
US20170281529A1 (en) 2017-10-05
SI2488157T1 (sl) 2021-02-26
EP2488157B1 (en) 2020-12-30
SMT202100150T1 (it) 2021-05-07
EP2488157A1 (en) 2012-08-22
US20120263766A1 (en) 2012-10-18
AU2010305695A1 (en) 2012-05-03
AU2010305695B2 (en) 2014-07-10
LT2488157T (lt) 2021-02-10
IL269369A (en) 2019-11-28
CY1123918T1 (el) 2022-05-27
BR112012008969A2 (pt) 2020-06-23
HRP20210379T1 (hr) 2021-04-16
EP3811928A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
ZA202208111B (en) Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
WO2009095681A3 (en) Suspension formulations
MX372991B (es) Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante.
MX2013012975A (es) Composiciones farmaceuticas.
ME02342B (me) Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom
MX2022008440A (es) Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada.
JP2014530231A5 (enExample)
WO2011076841A3 (en) Combination therapy for copd
HK1215388A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置
MX370890B (es) Composición que comprende sulfato de salbutamol.
JP2013507429A5 (enExample)
NZ600208A (en) Inhalation solutions
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
NZ591174A (en) Metered dose inhaler
TNSN07289A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
WO2006124954A3 (en) Inhalable formulations of amphotericin b and methods and devices for delivery thereof
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
WO2021146176A1 (en) Medicinal compositions for carbon dioxide based metered dose inhalers
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 OCT 2017 BY LEA SKYLLERSTEDT

Effective date: 20150609

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2018 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20170928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20200930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2022 BY CAMILLA WELLIN / CPA GLOBAL

Effective date: 20210929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20220924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2025 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20240916

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2026 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20250917